Search results for "Hypersensitivity pneumonitis"
showing 4 items of 4 documents
P164 Cyclophosphamide for the treatment of refractory chronic hypersensitivity pneumonitis
2018
Introduction Intravenous cyclophosphamide at a dose of 600 mg/m2 monthly for 6 months is an established treatment for various immune modulated interstitial lung diseases (ILDs). This practice has been extended to rapidly progressive chronic hypersensitivity pneumonitis (CHP), however, little is known about the therapeutic efficacy in this disease. Methods All patients receiving intravenous cyclophosphamide between 2007 and 2017 at the Royal Brompton Hospital were identified using pharmacy records. Those with a clinical diagnosis of CHP underwent MDT review to confirm the diagnosis. Clinical data, demographics and lung function at time of first treatment and 12 months pre- and post was captu…
Lung microenvironments and disease progression in fibrotic hypersensitivity pneumonitis
2022
Rationale: Fibrotic hypersensitivity pneumonitis (fHP) is an interstitial lung disease caused by sensitization to an inhaled allergen. Objectives: To identify the molecular determinants associated with progression of fibrosis. Methods: Nine fHP explant lungs and six unused donor lungs (as controls) were systematically sampled (4 samples/lung). According to microcomputed tomography measures, fHP cores were clustered into mild, moderate, and severe fibrosis groups. Gene expression profiles were assessed using weighted gene co-expression network analysis, xCell, gene ontology, and structure enrichment analysis. Gene expression of the prevailing molecular traits was also compared with idiopathi…
Hypersensitivity pneumonitis : Lessons from a randomized controlled trial in children
2021
Introduction Hypersensitivity pneumonitis (HP) in children is a severe interstitial lung disease and potentially, a chronic condition, if not treated appropriately. No evidence-based guidelines are available; in particular, the role of systemic glucocorticoid therapy is unclear. Methods The aim of this randomized, double-blind, placebo-controlled, parallel-group, multi-center, phase II trial in pediatric HP was to assess the outcome of HP in children after 6 months of treatment and to compare 3 months of treatment with oral prednisolone or placebo. Results After 1.5 years and the inclusion of only four children, we terminated the study prematurely. Two of the children randomized to predniso…
Iatrogenic pulmonary lesions.
2018
Treatment of patients often includes the administration of medications and sometimes radiation. While the intent is to treat an underlying condition, in some cases, adverse effects occur due to these agents. Most of these adverse effects are mild, however, some can be severe and life-threatening. Furthermore, while these effects are often reversible upon cessation of exposure, especially if the inciting agent is recognized and withdrawn early, others might be permanent or even progressing. Most common histopathologic findings in drug-induced interstitial lung disease include nonspecific interstitial pneumonia (cellular and/or fibrotic), organizing pneumonia with or without bronchiolitis, eo…